Engineering Technology Research Center is an important part of the enterprise R&D institution. Enterprises recognized as Suzhou Engineering Technology Research Center will implement higher standards in terms of organizational structure, operating mechanism, funding investment, talent cultivation, industry-university-research cooperation, etc., which is conducive to enterprises to continuously improve their independent innovation capabilities, enhance the core competitiveness of the industry, and further play the demonstration and promotion role of Suzhou Engineering Technology Research Center in regional industrial transformation and upgrading.

“Focus on technological innovation

Caring for heart health”

Weisi Medical is an innovative medical technology company focusing on ventricular arrhythmia prevention and treatment and heart rhythm data services. The company is committed to providing the world’s leading full-process complete solution for ventricular arrhythmia prevention, monitoring, treatment, and rehabilitation. It has developed two products with completely independent intellectual property rights-wearable automatic external defibrillator (WCD) and automatic external defibrillator (AED), and has initially established a data platform to provide remote services for users of such products.

In response to the current practical difficulties in the layout of AEDs, VIS has conducted in-depth research and vigorously promoted the three-dimensional layout of AEDs. Through the integrated and coordinated layout of fixed-position AEDs, mobile AEDs, and drone AEDs, the emergency rescue efficiency and AED coverage efficiency are significantly improved, helping to build a healthy China 2030 emergency rescue system suitable for Chinese characteristics.

In the face of urgent clinical needs in China, the company independently developed a wearable automatic external defibrillator (WCD) to provide continuous protection for patients at high risk of short-term sudden cardiac death during the wearing period. The product has entered the green channel for innovative medical device review in January 2021, and is expected to break the foreign monopoly and become China’s first WCD product.

In August 2022, VIS’s “Wearable Automatic External Defibrillator (WCD) and Sudden Death Risk Artificial Intelligence Assessment System” project was approved by the Ministry of Industry and Information Technology and the National Medical Products Administration, and was successfully selected as the unit for the innovation task of artificial intelligence medical devices, becoming the main body of the innovation task.

In the future, Vivis Medical will extend the development of the world’s first multi-parameter sudden death risk assessment system through the promotion of ventricular arrhythmia wearable products and remote data service management. Through this system, Vivis will lead the transformation of passive treatment of sudden cardiac death into precise treatment of ventricular arrhythmia rhythm management that combines prevention and treatment.

The 14th Five-Year Plan clearly points out that it is necessary to achieve breakthroughs in the core technologies of high-end medical equipment and accelerate the promotion of import substitution. Vivis Medical will continue to focus on the key core technologies of cardiac rhythm management to inject stronger impetus into accelerating the realization of import substitution of high-end medical equipment and realizing “Healthy China”.